DOCSLIB.ORG

Table of Contents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table of Contents Table of Contents PLENARY SESSIONS SPEAKER ABSTRACTS 5 A. Ageing and infectious diseases 6 B. H1N1 pandemic: Will vaccines solve the problem, and how will we know? 7 C. What has genotyping to offer epidemiologists 9 D. New methods for analyzing outbreaks 10 PARALLEL SESSIONS ABSTRACTS 13 01. Influenza 1 14 02. Outbreaks 1 16 03. Health care associated infections 1 19 04. Surveillance 1 21 05. Vaccine preventable diseases 1 24 06. HIV 26 07. Influenza 2 28 08. Food-and water-borne diseases 30 09. Surveillance 2 33 10. International Health 35 11. Vaccine preventable diseases 2 38 12. Health care associated infections 2 40 13. Environmental Epidemiology 43 14. Tuberculosis 45 15. Sexually Transmitted Infections 47 16. Influenza 3 49 17. Outbreaks 2 51 18. New methods in public health 54 19. Surveillance 3 56 20. Zoonozes 58 21. Antimicrobial resistance 61 LATE BREAKERS SESSION ABSTRACTS 65 POSTERS ABSTRACTS 69 A1. Antimicrobial resistance 70 A2. Food- and water-borne diseases 73 A3. Health care associated infections 79 A4. HIV - STI 84 A5. Influenza 87 A6. International health 93 A7. Molecular epidemiology 97 B1. Public health methodology and new approaches 99 B2. Epidemic intelligence activities 103 B3. Outbreaks 105 B4. Surveillance 110 B5. Tuberculosis 118 B6. Vaccine preventable diseases 121 B7. Vector borne diseases 129 B8. Zoonoses 131 INDEX By subject 136 By author 140 Abstract Book - ESCAIDE 2009 - 3 Plenary Session Speaker Abstracts Abstract Book - ESCAIDE 2009 - 5 Plenary Session Speaker Abstracts Reference: Plenary Session A Reference: Plenary Session A Ageing and infectious diseases Ageing and infectious diseases The times of our lives: The impact of current demographic a history of longevity change on the dynamics and control Professor Christopher Dye of childhood infectious diseases Office of HIV/AIDS, Tuberculosis, Malaria & Neglected Tropical Diseases , (measles as an example) World Health Organization, CH 1211 Geneva 27, Switzerland Professor Piero Manfredi (1), S. Merler (2), M. Ajelli (2), JR Williams (3), M. Iannelli (4) ABSTRACT 1. Dipartimento di Statistica & Matematica Applicata all'Economia, Università di Pisa, Italy 2. Predictive models for Biomedicine and Environment, Fondazione Bruno Kessler, Trento, Italy The massive increase in life expectancy that took place in 3. Department of Infectious Disease Epidemiology, Imperial College London. the industrialized world between 1800 and 1950 is among 4. Dipartimento di Matematica, Università di Trento, Italy the most remarkable facts in human biology. No one living in 18th century Europe could have foreseen the amazing plasticity of human life spans, or the potential for such rapid ABSTRACT change. I shall begin this talk by considering why life span doubled in Britain and other industrializing countries after During the last 30 years European populations have 1800. I shall investigate the underlying population processes, experienced a variety of changes, e.g. the generalised spread and identify the key interventions that changed mortality of low fertility, the "postponement" of life events, and the rates attributable due to infectious diseases. Longevity in increasing role of international immigration. In this talk we low- and middle-income countries did not improve until discuss the impact of demographic change on the dynamics well in the 20th century, showing some similarities, but also and control of childhood infectious disease (CID) from a some important differences, from earlier events in Europe. modelling perspective. We first clarify the circumstances Having reviewed the history and geography, I shall discuss under which demographic change might actually have an the interplay between aging, fertility, demographic change impact on CID dynamics. Then we review those, among and the global distribution of infectious diseases today. current demographic changes, which we believe to be mostly The growth in life expectancy must eventually stop, but it important for the dynamics and control of CID, i.e. fertility is debatable whether centenarians will become the norm or decline and immigration, and their impact on population and remain exceptional during the 21st century. household distributions. Next, we investigate the relation between population change and social contact patterns by a model of infection where contacts occur in three distinct arenas, i.e. the school (or work), the household, and "other" population contacts. We assume that school contacts are essentially unaffected by demographic change, owing to the common EU policy to keep fixed the average class size, so that most demographic change will be reflected in changes in household and other population contacts. We illustrate, under a variety of equilibrium or transient conditions, the effects of fertility decline on the corresponding contact matrices. By adding available estimates of arena-specific transmission rates we are able to compute basic reproduction numbers and therefore to figure out a relationship between degrees of fertility change and disease control conditions. Overall we suggest that for highly transmissible disease the impact of demographic change on transmission may be smaller than predicted in the literature (Manfredi-Williams 2005, Gao-Hethcote 2006), but a better understanding of transmission per arenas is certainly a need. Abstract Book - ESCAIDE 2009 - 6 Plenary Session Speaker Abstracts Reference: Plenary Session B Reference: Plenary Session B H1N1 pandemic: Will vaccines solve the problem, H1N1 pandemic: Will vaccines solve the problem, and how will we know? and how will we know? Overview of the current situation Assessing the effectiveness regarding H1N1 with particular of H1N1 vaccine in Europe emphasis on vaccine strategies Dr Alan Moren and prioritization I-MOVE Professor Angus Nicoll ECDC ABSTRACT To be published during session. ABSTRACT To be published during session. Abstract Book - ESCAIDE 2009 - 7 Plenary Session Speaker Abstracts Reference: Plenary Session B Reference: Plenary Session B H1N1 pandemic: Will vaccines solve the problem, H1N1 pandemic: Will vaccines solve the problem, and how will we know? and how will we know? Modelling the potential benefits H1N1 Vaccine uptake: of vaccine use Challenges for risk communication Mr Tommi Asikainen Professor Karl Ekdahl ECDC ECDC ABSTRACT ABSTRACT To be published during session. To be published during session. Abstract Book - ESCAIDE 2009 - 8 Plenary Session Speaker Abstracts Reference: Plenary Session C Reference: Plenary Session C What has genotyping to offer epidemiologists What has genotyping to offer epidemiologists Integrating strain typing Next generation molecular and epidemiology in international epidemiology of RNA viruses networks: focus on diphtheria and invasive group A streptococcal Dr Oliver Pybus infections University of Oxford, United Kingdom Dr Androulla Efstratiou ABSTRACT Health Protection Agency Centre for Infections, London, United Kingdom Molecular epidemiology is changing rapidly, due to the increasing abundance of pathogen genome sequences, acceleration in computer processing power, and the ABSTRACT development of sophisticated inference methods based on phylogenetics and population genetics. As a result, the range Two distinct bacterial diseases, namely diphtheria and of epidemiological questions that can be answered using invasive group A streptococcal infections (iGAS) will be genetic data has grown enormously. This is especially true for described to illustrate the relevance and importance RNA viruses, which evolve so quickly that their evolutionary of epidemiological strain typing amongst international and ecological dynamics occur on similar timescales and networks. Both diseases have the potential to cause are therefore coupled. I will illustrate the range of empirical significant morbidity and mortality on a global scale. questions open to current and next-generation methods of The main typing method for diphtheria is ribotyping, which evolutionary analysis, with reference to the hepatitis C virus has proved to be invaluable for the molecular epidemiology of and other human RNA viruses. I will also consider whether the 1990s epidemic in Europe; the largest outbreak since the the explosion in sequence data is outpacing our ability to advent of mass immunization. Cases are still being reported develop methods that fully exploit its potential. and the epidemic strain 'Sankt Petersburg' continues to circulate in the European Region. The situation is still being closely monitored by the international diphtheria networks DIPNET (European Diphtheria Surveillance Network) and the WHO/ELWGD (European Laboratory Working Group on Diphtheria). iGAS infections re-emerged globally in the 1980s and high incidence still persists. The 'global typing scheme' is based upon the emm gene which encodes the organism's key virulence factor the M protein, more than 200 emm types are currently described. GAS epidemiology varies with time in the long term and the short term where temporal variation of emm predominance is encountered, hence global diversity. An official network does not exist but in 2002, the European Commission funded research on iGAS infections (strep- EURO), with participation from 12 EU Members states. This 'adhoc' network investigated the epidemiology of these infections for the first time on a Pan-European scale and contributed significantly to epidemiology, raised awareness and provided data for future vaccine formulations and public health guidelines. There are many unanswered questions
Load more

Recommended publications
  • Cost, Affordability and Cost-Effectiveness of Strategies To
    BMC Public Health BioMed Central Research article Open Access Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence Christine SM Currie1, Katherine Floyd*2, Brian G Williams2 and Christopher Dye2 Address: 1School of Mathematics, University of Southampton, Southampton, SO17 1BJ, UK and 2HIV/AIDS, Tuberculosis and Malaria cluster, World Health Organization, 20 Avenue Appia, CH-1211 Geneva 27, Switzerland Email: Christine SM Currie - [email protected]; Katherine Floyd* - [email protected]; Brian G Williams - [email protected]; Christopher Dye - [email protected] * Corresponding author Published: 12 December 2005 Received: 07 April 2005 Accepted: 12 December 2005 BMC Public Health 2005, 5:130 doi:10.1186/1471-2458-5-130 This article is available from: http://www.biomedcentral.com/1471-2458/5/130 © 2005 Currie et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: The HIV epidemic has caused a dramatic increase in tuberculosis (TB) in East and southern Africa. Several strategies have the potential to reduce the burden of TB in high HIV prevalence settings, and cost and cost-effectiveness analyses can help to prioritize them when budget constraints exist. However, published cost and cost-effectiveness studies are limited. Methods: Our objective was to compare the cost, affordability and cost-effectiveness of seven strategies for reducing the burden of TB in countries with high HIV prevalence.
    [Show full text]
  • Establishment & Lineage Dynamics of the SARS-Cov-2 Epidemic in the UK
    medRxiv preprint doi: https://doi.org/10.1101/2020.10.23.20218446; this version posted October 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Establishment & lineage dynamics of the SARS-CoV-2 epidemic in the UK Louis du Plessis†1, John T. McCrone†2, Alexander E. Zarebski†1, Verity Hill†2, Christopher Ruis†3,4, Bernardo Gutierrez1,5, Jayna Raghwani1, Jordan Ashworth2, Rachel Colquhoun2, Thomas R. Connor6,7, Nuno R. Faria1,8, Ben Jackson2, Nicholas J. Loman9, Áine O’Toole2, Samuel M. Nicholls9, Kris V. Parag8, Emily Scher2, Tetyana I. Vasylyeva1, Erik M. Volz8, Alexander Watts12,13, Isaac I. Bogoch10,11, Kamran Khan10,12,13, the COVID-19 Genomics UK (COG-UK) Consortium+,14, David M. Aanensen15,16, Moritz U. G. Kraemer‡1, Andrew Rambaut*‡2, Oliver G. Pybus*‡1,17 1 Department of Zoology, University of Oxford, Oxford, UK. 2 Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK. 3 Molecular Immunity Unit, Department of Medicine, University of Cambridge, Cambridge, UK. 4 Department of Veterinary Medicine, University of Cambridge, Cambridge, UK. 5 School of Biological and Environmental Sciences, Universidad San Francisco de Quito USFQ, Quito, Ecuador. 6 School of Biosciences, Cardiff University, UK. 7 Pathogen Genomics Unit, Public Health Wales NHS Trust, UK. 8 MRC Centre for Global Infectious Disease Analysis, J-IDEA, Imperial College London, UK. 9 Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK.
    [Show full text]
  • Anti-Tuberculosis
    WHO/CDS/TB/2000.278 Anti-tuberculosis Drug Resistance in the World Anti-tuberculosis Communicable Diseases SURVEILLANCE GLOBALPROJECT ON ANTI-TUBERCULOSIS DRUG RESISTANCE THE WHO/IUATLD WORLD HEALTH ORGANIZATION ANTI-TUBERCULOSIS 20, avenue Appia CH-1211 Geneva 27 SWITZERLAND Telephone 41 22 791 2708 Facsimile 41 22 791 4268 Report No.2 Prevalence and Trends Prevalence and Trends Report No.2 THE WHO/IUATLD GLOBAL PROJECT ON ANTI-TUBERCULOSIS DRUG RESISTANCE SURVEILLANCE COMMUNICABLE DISEASES WORLD HEALTH ORGANIZATION WHO/CDS/TB/2000.278 Distr.: General Original: English ANTI-TUBERCULOSIS DRUG RESISTANCE IN THE WORLD Report No. 2 Prevalence and Trends The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance Communicable Diseases World Health Organization Geneva 2000 © World Health Organization, 2000 This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced or translated, in part or in whole, but not for sale nor for use in conjunction with commercial purposes. The views expressed in documents by named authors are solely the responsibility of those au- thors. WRITING COMMITTEE • Marcos A. Espinal, M.D., Dr.P.H., M.P.H., Communicable Diseases Surveillance & Response and Communicable Diseases Control, Prevention & Eradication, World Health Organization (WHO), Geneva, Switzerland; • Lone Simonsen, Ph.D., Communicable Diseases Surveillance & Response, WHO, Geneva, Switzerland; • Adalbert Laszlo, Ph.D., Laboratory Centre for Disease Control, Ottawa, Canada; International Union Against Tuberculosis and Lung Disease (IUATLD); • Fadila Boulahbal, Ph.D., Institut Pasteur, Alger, Algeria; • Sang Jae Kim, Sc.D., Korean Institute of Tuberculosis, Seoul, Republic of Korea; • Ana Reniero, Ph.D., Instituto Panamericano de Protección de Alimentos y Zoonosis, Buenos Aires, Argentina; • Sven Hoffner, Ph.D., Swedish Institute for Infectious Disease Control, Stockholm, Sweden; • Hans L.
    [Show full text]
  • World Bank Document
    Public Disclosure Authorized PRIORITIES Priorities in Health in Health Public Disclosure Authorized Public Disclosure Authorized Editors Dean T. Jamison Joel G. Breman Anthony R. Measham George Alleyne Mariam Claeson David B. Evans Prabhat Jha Anne Mills Philip Musgrove Disease Control Priorities Project Public Disclosure Authorized Priorities in Health Advisory Committee to the Editors J. R. Aluoch Christopher Lovelace Jacques Baudouy Anthony Mbewu Fred Binka Rajiv Misra Mayra Buvini´c Perla Santos Ocampo David Challoner G. B. A. Okelo Guy de Thé Sevket Ruacan Timothy Evans Pramilla Senanayake Richard Horton Jaime Sepúlveda Sharon Hrynkow Chitr Sitthi-amorn Gerald Keusch Sally Stansfield Kiyoshi Kurokawa Misael Uribe Peter Lachmann Zhengguo Wang Mary Ann Lansang Witold Zatonski Contributing Writers William D. Savedoff and Anne-Marie Smith, Social Insight Priorities in Health Editors Dean T. Jamison Joel G. Breman Anthony R. Measham George Alleyne Mariam Claeson David B. Evans Prabhat Jha Anne Mills Philip Musgrove THE WORLD BANK Washington, D.C. ©2006 The International Bank for Reconstruction and Development / The World Bank 1818 H Street NW Washington, DC 20433 Telephone: 202-473-1000 Internet: www.worldbank.org E-mail: [email protected] All rights reserved 123409080706 This volume was funded in part by a grant from the Bill & Melinda Gates Founda- tion and is a product of the staff of the International Bank for Reconstruction and Development / The World Bank, the World Health Organization, and the Fogarty International Center of the National Institutes of Health. The findings, interpreta- tions, and conclusions expressed in this volume do not necessarily reflect the views of the Executive Directors of The World Bank or the governments they represent, the World Health Organization, or the Fogarty International Center of the National Institutes of Health.
    [Show full text]
  • 80 Questions for UK Biological Security
    80 questions for UK biological security Kemp, L., Aldridge, D. C., Booy, O., Bower, H., Browne, D., Burgmann, M., Burt, A., Cunningham, A. A., Dando, M., Dick, J. T. A., Dye, C., Evans, S. W., Gallardo, B., Godfray, C. H. J., Goodfellow, I., Gubbins, S., Holt, L. A., Jones, K. E., Kandil, H., ... Sutherland, W. J. (2021). 80 questions for UK biological security. PLoS ONE, 16(1 ), [e0241190]. https://doi.org/10.1371/journal.pone.0241190 Published in: PLoS ONE Document Version: Publisher's PDF, also known as Version of record Queen's University Belfast - Research Portal: Link to publication record in Queen's University Belfast Research Portal Publisher rights Copyright 2021 the authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited. General rights Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact [email protected].
    [Show full text]
  • Disease Control Priorities in Developing Countries SECOND EDITION
    Disease Control Priorities in Developing Countries SECOND EDITION Disease Control Priorities in Developing Countries SECOND EDITION Editors Dean T. Jamison Joel G. Breman Anthony R. Measham George Alleyne Mariam Claeson David B. Evans Prabhat Jha Anne Mills Philip Musgrove A copublication of Oxford University Press and The World Bank ©2006 The International Bank for Reconstruction and Development / The World Bank 1818 H Street NW Washington DC 20433 Telephone: 202-473-1000 Internet: www.worldbank.org E-mail: [email protected] All rights reserved 1 2 3 4 09 08 07 06 A copublication of The World Bank and Oxford University Press. Oxford University Press 165 Madison Avenue New York NY 10016 This volume was funded in part by a grant from the Bill & Melinda Gates Foundation and is a product of the staff of the International Bank for Reconstruction and Development / the World Bank, the World Health Organization, and the Fogarty International Center of the National Institutes of Health. The findings, inter- pretations, and conclusions expressed in this volume do not necessarily reflect the views of the executive direc- tors of the World Bank or the governments they represent, the World Health Organization, or the Fogarty International Center of the National Institutes of Health. The World Bank, the World Health Organization, and the Fogarty International Center of the National Institutes of Health do not guarantee the accuracy of the data included in this work. The boundaries, colors, denominations, and other information shown on any map in this work do not imply any judgement on the part of the World Bank, the World Health Organization, or the Fogarty International Center of the National Institutes of Health concerning the legal status of any territory or the endorsement or acceptance of such boundaries.
    [Show full text]
  • Download Download
    Res Medica, Volume 21, Issue 1 Page 1 of 11 SPECIAL ARTICLE The World Health Report 1995-2013: A personal retrospective Thomson Prentice Former Managing Editor World Health Organization Correspondence email: [email protected] Abstract Thomson Prentice shares his personal experiences of being part of the World Health Reports (WHR) from 1995-2013. Copyright Royal Medical Society. All rights reserved. The copyright is retained by the author and the Royal Medical Society, except where explicitly otherwise stated. Scans have been produced by the Digital Imaging Unit at Edinburgh University Library. Res Medica is supported by the University of Edinburgh’s Journal Hosting Service: http://journals.ed.ac.uk ISSN: 2051-7580 (Online) ISSN: 0482-3206 (Print) Res Medica is published by the Royal Medical Society, 5/5 Bristo Square, Edinburgh, EH8 9AL Res Medica, 2013, 21(1):2-11 doi: 10.2218/resmedica.v21i1.510 Prentice, T. The World Health Report 1995-2013: A personal retrospective. Res Medica 2013, 21(1), pp.2-11 doi:10.2218/resmedica.v21i1.510 Prentice T. http://journals.ed.ac.uk/resmedica Introduction In my experience, I can say that every report SPECIAL The launch of The World Health Report has been a unique exercise, invariably (WHR) 2013 in Beijing in September of this complex, involving many people in WHO year brought the total of such reports to 16 HQ, Regional Offices and elsewhere, and since the World Health Organization many individual contributors. The work usually spanned about 12 months. Often (WHO) brought out the first edition in 1995.1 During that time the WHR has that seemed barely long enough for some of become WHO’s flagship publication and an us, and far too long for others.
    [Show full text]
  • Membership of Sectional Committees 2015
    Membership of Sectional Committees 2015 The main responsibility of the Sectional Committees is to select a short list of candidates for consideration by Council for election to the Fellowship. The Committees meet twice a year, in January and March. SECTIONAL COMMITTEE 1 [1963] SECTIONAL COMMITTEE 3 [1963] Mathematics Chemistry Chair: Professor Keith Ball Chair: Professor Anthony Stace Members: Members: Professor Philip Candelas Professor Varinder Aggarwal Professor Ben Green Professor Harry Anderson Professor John Hinch Professor Steven Armes Professor Christopher Hull Professor Paul Attfield Professor Richard Kerswell Professor Shankar Balasubramanian Professor Chandrashekhar Khare Professor Philip Bartlett Professor Steffen Lauritzen Professor Geoffrey Cloke Professor David MacKay Professor Peter Edwards Professor Robert MacKay Professor Malcolm Levitt Professor James McKernan Professor John Maier Professor Michael Paterson Professor Stephen Mann Professor Mary Rees Professor David Manolopoulos Professor John Toland Professor Paul O’Brien Professor Srinivasa Varadhan Professor David Parker Professor Alex Wilkie Professor Stephen Withers SECTIONAL COMMITTEE 2 [1963] SECTIONAL COMMITTEE 4 [1990] Astronomy and physics Engineering Chair: Professor Simon White Chair: Professor Hywel Thomas Members: Members: Professor Girish Agarwal Professor Ross Anderson Professor Michael Coey Professor Alan Bundy Professor Jack Connor Professor Michael Burdekin Professor Laurence Eaves Professor Russell Cowburn Professor Nigel Glover Professor John Crowcroft
    [Show full text]
  • The Scale and Dynamics of COVID-19 Epidemics Across Europe
    medRxiv preprint doi: https://doi.org/10.1101/2020.06.26.20131144; this version posted August 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. The scale and dynamics of COVID-19 epidemics across Europe Authors: Christopher Dye,1 Russell C.H. Cheng,2 John S. Dagpunar2 & Brian G. Williams3 5 Affiliations: 1. Department of Zoology, University of Oxford, United Kingdom 2. Department of Mathematical Sciences, University of Southampton, United Kingdom 10 3. South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, South Africa. * Correspondence to: [email protected] Abstract: 15 The number of COVID-19 deaths reported from European countries has varied more than 100-fold. In terms of coronavirus transmission, the relatively low death rates in some countries could be due to low intrinsic (e.g. low population density) or imposed contact rates (e.g. non-pharmaceutical interventions) among individuals, or because fewer people 20 were exposed or susceptible to infection (e.g. smaller populations). Here we develop a flexible empirical model (skew-logistic) to distinguish among these possibilities. We find that countries reporting fewer deaths did not generally have intrinsically lower rates of transmission and epidemic growth, and flatter epidemic curves. Rather, countries with fewer deaths locked down earlier, had shorter epidemics that peaked sooner, and smaller 25 populations. Consequently, as lockdowns are eased we expect, and are starting to see, a resurgence of COVID-19 across Europe.
    [Show full text]
  • The Neglected Dimension of Global Security a Framework to Counter Infectious Disease Crises
    The Neglected Dimension of Global Security A Framework to Counter Infectious Disease Crises www.nam.edu/GHRF PREPUBLICATION COPY: UNCORRECTED PROOFS NOTICE: Statements, recommendations, and opinions expressed are those of the Commission on a Global Health Risk Framework for the Future (GHRF Commission). The National Academy of Medicine served as Secretariat for the GHRF Commission, with support from the following National Academies of Sciences, Engineering, and Medicine staff: Carmen C. Mundaca-Shah, Project Director V. Ayano Ogawa, Research Associate Priyanka Kanal, Intern (until July 2015) David Garrison, Senior Program Assistant (from December 2015) Mariah Geiger, Senior Program Assistant (until December 2015) Faye Hillman, Financial Officer Patrick W. Kelley, Director, Board on Global Health Consultants Anas El-Turabi, Doctoral Candidate in Health Policy (Evaluative Science & Statistics), Graduate School of Arts and Sciences, Harvard University Philip Saynisch, Doctoral Candidate in Health Policy, Harvard Business School and Graduate School of Arts and Sciences, Harvard University Sponsors The Commission was supported by the Paul G. Allen Family Foundation, the Ford Foundation, the Bill & Melinda Gates Foundation, Mr. Ming Wai Lau, the Gordon and Betty Moore Foundation, the Rockefeller Foundation, the United States Agency for International Development, and Wellcome Trust. Copyright 2016 by the Commission on a Global Health Risk Framework for the Future. Suggested citation: GHRF Commission (Commission on a Global Health Risk Framework
    [Show full text]
  • Membership of Sectional Committees 2014
    Membership of Sectional Committees 2014 The main responsibility of the Sectional Committees is to select a short list of candidates for consideration by Council for election to the Fellowship. The Committees meet twice a year, in January and March. SECTIONAL COMMITTEE 1 [1963] SECTIONAL COMMITTEE 3 [1963] Mathematics Chemistry Chair: Professor Peter McCullagh Chair: Professor Anthony Stace Members: Members: Professor Keith Ball Professor Varinder Aggarwal Professor Philip Candelas Professor Shankar Balasubramanian Professor Michael Duff Professor Philip Bartlett Professor Georg Gottlob Professor Peter Bruce Professor Ben Green Professor Eleanor Campbell Professor Richard Kerswell Professor Geoffrey Cloke Professor Robert MacKay Professor Peter Edwards Professor James McKernan Professor Craig Hawker Professor Michael Paterson Professor Philip Kocienski Professor Mary Rees Professor Malcolm Levitt Professor Andrew Soward Professor David Manolopoulos Professor John Toland Professor Paul O’Brien Professor Srinivasa Varadhan Professor David Parker Professor Alex Wilkie Professor Ezio Rizzardo Professor Trevor Wooley Professor Stephen Withers SECTIONAL COMMITTEE 2 [1963] SECTIONAL COMMITTEE 4 [1990] Astronomy and physics Engineering Chair: Professor Simon White Chair: Professor Keith Bowen Members: Members: Professor Gabriel Aeppli Professor Ross Anderson Professor Girish Agarwal Professor Alan Bundy Professor Michael Coey Professor John Burland Professor Jack Connor Professor Russell Cowburn Professor Stan Cowley Dame Ann Dowling Professor
    [Show full text]
  • Michel Foucault Ronald C Kessler Graham Colditz Sigmund Freud
    ANK RESEARCHER ORGANIZATION 1 Michel Foucault Collège de France 2 Ronald C Kessler Harvard University 3 Graham Colditz Washington University in St Louis 4 Sigmund Freud University of Vienna Brigham and Women's Hospital 5 JoAnn E Manson Harvard Medical School 6 Shizuo Akira Osaka University Centre de Sociologie Européenne; 7 Pierre Bourdieu Collège de France Massachusetts Institute of Technology 8 Robert Langer MIT 9 Eric Lander Broad Institute Harvard MIT 10 Bert Vogelstein Johns Hopkins University Brigham and Women's Hospital 11 Eugene Braunwald Harvard Medical School Ecole Polytechnique Fédérale de 12 Michael Graetzel Lausanne 13 Frank B Hu Harvard University 14 Yi Hwa Liu Yale University 15 M A Caligiuri City of Hope National Medical Center 16 Gordon Guyatt McMaster University 17 Salim Yusuf McMaster University 18 Michael Karin University of California San Diego Yale University; Howard Hughes 19 Richard A Flavell Medical Institute 20 T W Robbins University of Cambridge 21 Zhong Lin Wang Georgia Institute of Technology 22 Martín Heidegger Universität Freiburg 23 Paul M Ridker Harvard Medical School 24 Daniel Levy National Institutes of Health NIH 25 Guido Kroemer INSERM 26 Steven A Rosenberg National Institutes of Health NIH Max Planck Institute of Biochemistry; 27 Matthias Mann University of Copenhagen 28 Karl Friston University College London Howard Hughes Medical Institute; Duke 29 Robert J Lefkowitz University 30 Douglas G Altman Oxford University 31 Eric Topol Scripps Research Institute 32 Michael Rutter King's College London 33
    [Show full text]